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In Saccharomyces cerevisiae, absence of the checkpoint
kinaseMec1 (ATR) is viable uponmutations that increase
the activity of the ribonucleotide reductase (RNR) com-
plex. Whether this pathway is conserved in mammals re-
mains unknown. Here we show that cells from mice
carrying extra alleles of the RNR regulatory subunit
RRM2 (Rrm2TG) present supraphysiological RNR activity
and reduced chromosomal breakage at fragile sites. More-
over, increased Rrm2 gene dosage significantly extends
the life span of ATR mutant mice. Our study reveals the
first genetic condition in mammals that reduces fragile
site expression and alleviates the severity of a progeroid
disease by increasing RNR activity.
Supplemental material is available for this article.
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Replication stress (RS) has emerged as a source of genome
instability in human diseases, including cancer and pre-
mature aging (Lecona and Fernandez-Capetillo 2014;
Zeman and Cimprich 2014). In brief, RS is defined by
the accumulation of abnormal amounts of ssDNA at
stalled replication forks that, due to its recombinogenic
nature, can initiate genomic rearrangements. In mam-
mals, RS is sensed and suppressed by a signaling cascade
initiated by the ATR kinase, which, together with its tar-
get kinase, CHK1, suppresses RS through the phosphory-
lation of multiple targets (Cimprich and Cortez 2008;
Lopez-Contreras and Fernandez-Capetillo 2010). ATR
and CHK1 are essential for embryonic development in
mice (Brown and Baltimore 2000; de Klein et al. 2000;
Liu et al. 2000), which is due to the role of the RS response
(RSR) in preventing replication-born chromosome break-
age. Whether the RSR protects all forks or a subset of
them during replication is unclear. On the one hand, pro-
teomic studies of the human replisome in unchallenged
conditions have failed to detect ATR or CHK1 in the vi-
cinity of replication forks (Lopez-Contreras et al. 2013;
Sirbu et al. 2013), suggesting that their activity might be
particularly necessary for only a subset of forks, such as
damaged ones. Accordingly, chromosomal breaks that
arise upon ATR inactivation locate preferentially at spe-
cific loci named common fragile sites (CFSs) (Casper
et al. 2002) and early replicating fragile sites (ERFSs) (Bar-
low et al. 2013). Regardless of whether ATR works at all
forks or only some of them, how it suppresses RS and
why it is essential are still not fully understood.
Ribonucleotide reductase (RNR) is a tetrameric en-
zyme composed of two catalytic (RRM1, Rnr1 in yeast)
and two regulatory (RRM2, Rnr2 in yeast) subunits (Jor-
dan and Reichard 1998). It reduces NDPs into dNDPs,
which is a rate-limiting step for the production of dNTPs.
In yeast, the lethality ofmec1Δ strains can be bypassed by
mutations that increase RNR activity. The first evidence
of a connection between ATR and RNR came from the
discovery of Crt1 (a transcriptional repressor of RNR sub-
units) as a suppressor of Mec1 lethality in Saccharomyces
cerevisiae (Huang et al. 1998). Furthermore, overproduc-
tion of Rnr1 was shown to be sufficient to rescue
mec1Δ viability (Desany et al. 1998; Vallen and Cross
1999). In addition to the transcriptional regulation provid-
ed by Crt1, Mec1 and its downstream kinase, Dun1, also
increase RNR activity by phosphorylating the RNR in-
hibitor Sml1, leading to its degradation (Zhao et al.
2001; Zhao and Rothstein 2002). As in the case of Crt1,
sml1 deletion also rescued mec1Δ viability (Zhao et al.
1998). Finally, the activity of yeast RNR is also regulated
through the control of Rnr2 localization. S. cerevisiae
Dif1 or Schizosaccharomyces pombe Spd1 retain Rnr2
in the nucleus, preventing its interaction with cytoplas-
mic Rnr1. Like Crt1 or Sml1, deletion of spd1 or dif1 in-
creases RNR activity and suppresses the lethality of
checkpoint mutants (Liu et al. 2003; Lee et al. 2008; Wu
andHuang 2008). Even though no clear orthologs for yeast
RNR inhibitory proteins have been found in mammals,
evidence suggests that the connection between ATR
and RNR is conserved to some extent.
First, the addition of nucleosides has been shown to
reduce RS in various instances, such as in response to
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oncogenes or during zebrafish development (Bester et al.
2011; Danilova et al. 2014). Furthermore, CHK1 activa-
tion by topoisomerase inhibitors induces the expression
of RRM2 through E2F-dependent transcription (Zhang
et al. 2009). In addition, p53 induces the expression of an
alternative regulatory subunit (RRM2B or p53R2). How-
ever, both of these activities occur only after a prolonged
exposure to DNA damage and cannot account for the
more immediate role that ATR plays during DNA replica-
tion. Regarding Sml1, a recent study reported that IRBIT, a
protein known to be involved in ion transport, shares
some distant homology with Sml1 in a small fragment
of its sequence (Arnaoutov and Dasso 2014). This frag-
ment can bind and inhibit the RNR complex, but its activ-
ity seems to be restricted to mitosis and RRM1/RRM2B
complexes. In summary, while these experiments suggest
that RNR regulation might suppress RS in mammals,
whether and how these functions are linked to ATR activ-
ity are not understood.
Here we sought to explore the impact of the RNR in the
ATR response in mammals. To this end, we generated a
mouse model with increased levels of the regulatory sub-
unit RRM2 (Rrm2TG). We show that Rrm2 transgenic
mice present supraphysiological RNR activity, which be-
comes protective in the context of insufficient dNTP lev-
els. Importantly, we show that increased levels of RRM2
can limit chromosome breakage in response to ATR in-
hibitors and extend the life span of mice with reduced
ATR levels. Altogether, our findings provide strong genet-
ic support for the concept that regulating nucleotide pools
is one of the key functions of ATR in mammals.
Results and Discussion
Nucleosides limit RS and improve growth of ATR-Seckel
mouse embryonic fibroblasts (MEFs)
To explore whether increased nucleotides could suppress
phenotypes related to ATR deficiency in mammals, we
used MEFs from a model of the ATR-Seckel syndrome
(Murga et al. 2009). ATR-SeckelMEFs present severely re-
duced ATR levels and undergo premature senescence due
to the accumulation of RS (Murga et al. 2009; Monasor
et al. 2013).While nucleotides are not cell-permeable, a re-
cent report showed that the addition of nucleosides, the
nucleotide precursors, to the culture medium alleviates
oncogene-induced RS (Bester et al. 2011). In the case of
ATR-Seckel MEFs, the addition of nucleosides signifi-
cantly reduced the levels of RS, as quantified by measur-
ing the phosphorylation status of histone H2AX
(γH2AX) or the ssDNA-binding protein RPA by high-
throughputmicroscopy (HTM) (Fig. 1A,B). In addition, nu-
cleoside supplementation to the culturemediumpartially
rescued the growth defect in three independent lines of
ATR-Seckel MEFs (Fig. 1C,D). These results suggest that
increased levels of nucleotides can suppress the RS that
derives from reduced ATR activity.
Generation of a mouse model with increased
RRM2 levels
To investigate the consequences of increased RNR activ-
ity in amammalian organism,we generatedmice carrying
extra alleles of the regulatory subunit RRM2.We chose to
focus on RRM2 because of the following considerations.
First, knockdown of RRM2 increased RS in response to
the RNR inhibitor hydroxyurea (HU) in human U2OS
cells, whereas overexpression had the opposite effect
(Fig. 2A,B; Supplemental Fig. S1). Second, availablemicro-
array analyses revealed reduced levels of RRM2 expres-
sion on ATR-Seckel embryos (Murga et al. 2009),
suggesting that a defective RNR activitymight contribute
to the phenotypes of these mice. Third, ATR-dependent
degradation of cyclin F has been shown to increase
RRM2 levels in response to DNA damage (D’Angiolella
et al. 2012). Finally, classic reports described HU-resistant
hamster cell lines that were associated with genomic am-
plification of Rrm2, but not Rrm1, which led to increased
RNR activity in these cells (Lewis andWright 1974; Tonin
et al. 1987). Hence, we hypothesized that mice carrying
additional copies of the Rrm2 gene would similarly have
increased RNR activity. To preserve the endogenous reg-
ulation of Rrm2 transcription, we subcloned a 26-kb re-
gion encompassing the Rrm2 gene and 10 kb of flanking
sequences (Fig. 2C). This strategy, in contrast to classic
transgenesis using plasmids harboring cDNA, has been
proven successful for generating animals with increased
activity of genes that are otherwise deleteriouswhen aber-
rantly overexpressed, such as Chk1 or Tp53 (Garcia-Cao
et al. 2002; Lopez-Contreras et al. 2012).
Transgenic lines were identified by Southern blotting,
and the integration site was subsequently mapped by in-
verse PCR. We selected one line (Rrm2TG) carrying sever-
al alleles integrated in tandem (Fig. 2D) on the basis of
having the insertion of the transgene at a locus where it
did not disrupt any other gene (chr12: 118,863,235). Map-
ping the insertion also allowed for genotyping of homozy-
gous or heterozygous mice (Fig. 2E). Rrm2 transgenic
Figure 1. Nucleoside supplementation reduces RS and improves
growth of ATR-Seckel MEFs. (A) HTM-mediated quantification of
the intensity of γH2AX per individual nucleus on Atr+/+ and AtrS/S
MEFs treated or not with 60 μM nucleosides for 24 h. Data are repre-
sentative of two independent cell lines. (B) HTM-mediated quantifi-
cation of the intensity of phosphorylated RPA per individual
nucleus on Atr+/+ and AtrS/S MEFs treated or not with 60 μM nucleo-
sides for 24 h. Data are representative of two independent cell lines.
(C ) Proliferation curves of Atr+/+ and AtrS/S MEFs grown in the pres-
ence or absence of 60 μM nucleoside supplementation. Data are rep-
resentative of two independent analyses. (D) Representative
pictures of wild-type and ATR-Seckel MEFs at the end point of the
proliferation assay shown in C. Note that while all ATR mutant
MEFs show the flattened morphology of senescent cells at this point,
those treated with a nucleoside supplement still present cells with
the elongated morphology of proliferating fibroblasts. (∗∗∗) P < 0.001.
Rescue of ATR-Seckel with RRM2
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MEFs exhibited increased RRM2 protein levels in a trans-
gene dosage-dependent manner, as detected by Western
blotting and immunofluorescence (Fig. 2F,G). In contrast,
no effect on the levels of RRM1 or ATR was observed. In
tissues, RRM2 expression was analyzed by immunohisto-
chemistry (IHC). RRM2 expression was highest in tissues
with active turnover, such as spleen or testes, and in-
creased on Rrm2 transgenic tissues (Supplemental Fig.
S2). Interestingly, RRM2 was cytoplasmic in all tissues
except testes, where it showed a nuclear distribution
consistent with nuclear RNR activity being particularly
relevant for DNA repair (D’Angiolella et al. 2012). Regard-
less of its increased expression, the intracellular local-
ization of RRM2 or its relative abundance between
different tissues was not altered on Rrm2TG mice. Thus,
mice carrying extra alleles of Rrm2 provide a physiologi-
cal model to investigate the consequences of increased
RRM2 levels.
Increased RNR activity in Rrm2TG MEFs
Two independent methods for quantifying dNTP levels
failed to detect significant changes on Rrm2 transgenic
MEFs (Supplemental Fig. S3). The absence of an increase
in steady-state dNTP levels is in agreement with the
existence of feedback inhibitory loops, which inhibit
RNR activity when dATP levels increase above physio-
logical levels (Jordan and Reichard 1998). Nevertheless,
our finding is in agreement with previous studies. For in-
stance, HU-resistant mouse mammary tumor cells with a
40-fold overexpression of RRM2 have normal dNTP lev-
els (Eriksson et al. 1984). In addition, mouse 3T6 cells
made HU-resistant upon a gradual increase in HU con-
centrations have normal levels of dNTPs despite having
a threefold to 15-fold increase in RNR activity (Akerblom
et al. 1981). Hence, while steady-state dNTP levels are
kept at normal levels on Rrm2 transgenic cells, they
could harbor increased RNR activity that would be partic-
ularly relevant in conditions of limited nucleotide
availability.
To examine whether Rrm2 transgenic cells had in-
creased RNR activity, we tested how they responded to
the RNR inhibitor HU. A number of independent experi-
ments validated that Rrm2 transgenic cells had increased
RNR activity. First, HTM analyses revealed that Rrm2TG
MEFs exhibited lower levels of γH2AX in response to HU
(Fig. 3A). While Rrm2TG/TG MEFs express more RRM2
than heterozygous cells, this did not translate into a high-
er resistance. This could indicate that the strategy of in-
creasing RRM2 might reach a limit if not done together
with a concomitant increase in RRM1. Besides H2AX,
Rrm2 transgenic MEFs also presented lower levels of
RPA phosphorylation in response to HU (Fig. 3B). In
Figure 2. Generation of Rrm2TG mice. (A) HTM-mediated quantifi-
cation of the intensity of γH2AX per individual nucleus on human
U2OS cells 48 h after being transfected with endogenous siRNAs
(esiRNAs) targeting either firefly luciferase (Luc) or Rrm2. Where in-
dicated, cells were also exposed to 2 mM HU for 3 h. Data are repre-
sentative of two independent experiments. (B) HTM-mediated
quantification of the intensity of γH2AX per individual nucleus on
human U2OS cells 48 h after being transfected with a RRM2-express-
ing plasmid or the empty vector (control). Where indicated, cells were
also exposed to 2mMHU for 3 h. Data are representative of two inde-
pendent experiments. (C ) Scheme of the genomic locus (including the
Rrm2 gene and flanking regions) that was used for the generation of
Rrm2TG mice. (D) Southern blot illustrating the presence of a single
transgene integration site (5 kb) on the Rrm2TG strain. The 9-kb
band corresponds to the endogenous Rrm2 gene. (E) Genotyping
PCR illustrating the three genotypes that can be obtained at Mende-
lian ratios on the Rrm2TG strain. (F ) Western blot illustrating the lev-
els of RRM2, RRM1, andATRonRrm2+/+,Rrm2+/TG, andRrm2TG/TG
MEFs. β-Actin was used as a loading control. (G) HTM-mediated
quantification of the intensity of RRM2 per individual cell on
Rrm2+/+,Rrm2+/TG, andRrm2TG/TGMEFs. RRM2Western blot of tis-
sues from wild-type and Rrm2Tg mice. (∗∗∗) P < 0.001.
Figure 3. Increased RNR activity on Rrm2TG cells. (A) HTM-medi-
ated quantification of the intensity of γH2AX per individual nucleus
on Rrm2+/+, Rrm2+/TG, and Rrm2TG/TG MEFs. Data are representa-
tive of three independent experiments. Where indicated, cells were
also exposed to 0.5 mMHU for 4 h. (B) HTM-mediated quantification
of the intensity of phosphorylated RPA per individual nucleus on
Rrm2+/+ and Rrm2+/TG MEFs. Data are representative of three inde-
pendent experiments. Where indicated, cells were also exposed to
0.5mMHU for 4 h. Data are representative of three independent anal-
yses in four different MEF pairs. (C ) HTM-mediated quantification of
γH2AX and EdU intensities per individual nucleus in wild-type and
Rrm2 transgenic MEFs treated or not with 0.3 mM HU for 4 h. EdU
was added to the cultures for the last 30 min of the experiment.
Blue dots represent EdU-incorporating cells. (D) HTM-mediated
quantification of cell death by analysis the incorporation of the TO-
PRO-3 dye in Rrm2+/+ and Rrm2+/TG treated or not with 0.3 mM
HU for 24 h (see the Materials and Methods). The experiment was
done in triplicate with three independent MEF pairs. (∗∗∗) P < 0.001.
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addition to RS markers, Rrm2 transgenic cells were able
to incorporate EdU at doses of HU that fully prevented
replication in wild-type cells (Fig. 3C). Interestingly,
EdU incorporation in Rrm2+/TG MEFs could even be de-
tected in cells that presented H2AX phosphorylation. Of
note, the actual degree of HU-resistant replication might
be higher than observed with this assay, since higher
dNTP levels on Rrm2 transgenic cells exposed to HU
would compete with EdU during replication. Finally, we
tested actual HU resistance by looking at HU-induced cy-
totoxicity upon prolonged exposure to the drug. Once
again, increased levels of RRM2 correlated with lower lev-
els of HU-induced cell death in transgenic cells (Fig. 3D).
In contrast, Rrm2 transgenic cells were not protected
against other RS-inducing agents, such as aphidicolin or
camptothecin, suggesting that increased RRM2 levels be-
come particularly relevant in the context of conditions
that limit dNTP levels, such as HU or ATR inhibitors
(see below). Of note, neither the Rrm2 transgene nor the
supplementation of nucleosides shown above affected
cell cycle progression. Altogether, these experiments
demonstrate thatRrm2TG cells present increasedRNRac-
tivity, which protects them from HU-induced RS and
might be beneficial in the context of conditions that re-
duce dNTP availability.
Rrm2TG protects from reduced ATR activity
in vitro and in vivo
As mentioned, evidence from yeast suggests that stimu-
lating RNR activity is one of the essential activities of
Mec1 (ATR). To determine whether a similar interaction
might be conserved in mammals, we first tested whether
Rrm2TG cells were resistant to the replicative damage in-
duced by ATR inhibitors previously developed in our
group (Toledo et al. 2011). To do this, we looked at the
presence of chromosomal abnormalities at CFS and
ERFS loci, both of which are sites of preferential chromo-
somal fragility upon ATR inhibition (Casper et al. 2002;
Barlow et al. 2013). Proliferating B lymphocytes from
Rrm2TG cells presented an overall reduction in the num-
ber of chromosome breaks that were induced by ATR in-
hibitors (Fig. 4A), a difference that was pronounced at
CFS and ERFS fragile loci (Fig. 4B,C). Remarkably, ATR
inhibitors lead to a reduction in cellular dNTP levels (Sup-
plemental Fig S4), which might contribute to the toxicity
of these compounds. Supporting this view, increased lev-
els of RRM2 limit the chromosomal breakage that arises
upon ATR inhibition in vitro.
Finally, to determine whether increased RNR activity
could also rescue the phenotypes associated with defi-
cient ATR signaling in a mammalian organism, we
crossed Rrm2TG mice into the ATR-Seckel strain. The
Seckel syndrome was originally named “bird-headed
dwarfism” because of the overall reduced size and the cra-
niofacial anomalies present in these patients (Seckel
1960). Both of these clinical manifestations, which are re-
capitulated on ATR-Seckel mice, were significantly alle-
viated by the Rrm2 transgene (Fig. 4D,E). In addition to
the overall appearance, Seckelmice succumb prematurely
due to accelerated aging (Murga et al. 2009). Importantly,
the presence of the Rrm2 transgene significantly in-
creased the survival of ATR-Seckel mice (Fig. 4F). AtrS/S;
Rrm2TG/+ animals doubled the median life span of AtrS/S;
Rrm2+/+mice (50wk vs. 24wk).Moreover, the presence of
the transgene also increased the maximum life span of
ATR hypomorphic mice from 54 wk to 91 wk. Collective-
ly, these results demonstrate that increased RNR activity
limits the consequences derived from reduced ATR activ-
ity in mammals.
Here we show that RNR activity can be enhanced in
mammals by overexpression of the RRM2 subunit. A pre-
vious report that generated cDNA-based RNR transgenic
mice revealed that broad overexpression of RRM2 increas-
es the incidence of lung neoplasms (Xu et al. 2008). So far,
we failed todetect ahigher incidenceof tumorsonRrm2TG
mice. It is possible that the difference between these stud-
ies relies on the fact that our transgenicRRM2 is expressed
under its endogenous promoter so that we are not overex-
pressing highly increased levels in tissues where RNR ex-
pression is normally low (such as the lungs). To further
clarify this issue, we forced the development of lung tu-
mors on Rrm2TG mice by crossing them with a genetic
model of lung carcinogenesis induced by the K-Ras onco-
gene (Guerra et al. 2003),wherewealso failed to see signifi-
cant differences (Supplemental Fig. S5). Hence, the
increased RNR activity ofRrm2TGmice does not promote
cancer, which is consistent with the fact that dNTPs are
kept within normal levels in RRM2-overexpressing cells.
In contrast, our work reveals that increased RRM2 levels
can diminish the severity of the pathologies that lead to
the premature aging and death of ATR mutant mice.
Work in yeast has recently shown that increased RNR ac-
tivity reduces genomic instability in several DNA repair
Figure 4. Increased RNR activity limits chromosome breakage in re-
sponse to ATR inhibition and prolongs survival of ATR-Seckel mice.
(A) DNA aberrations per metaphase were counted from Rrm2+/+ and
Rrm2+/TG B lymphocytes treated with 10 μm ATR inhibitor for 16
h. Data were normalized as fold change from wild-type levels to ac-
count for fluctuations between three independent experimental
runs. (B) Aberrations at the GIMAP ERFS and the FHIT (FRA14A2)
per metaphase normalized as fold change from wild-type levels
from the metaphases used in A. Aberrations included chromatid
and chromosome breaks, radials, and dicentric chromosomes. At
least 84 metaphases were scored per replicate. (C, top panel) Diagram
of FISH probes, with the DNA in blue, telomeres in red, and BAC
probes in green. The bottom panel shows representative rearrange-
ments at GIMAP and FHIT. (D) The weight of ATRS/S;Rrm2+/+ and
ATRS/S;Rrm2+/TG male (left) and female (right) mice at 10 wk of
age. (E) The cranial length of ATRS/S;Rrm2+/+ and ATRS/S;Rrm2+/TG
mice at 10 wk of age analyzed by computerized tomography (CT).
(F ) Kaplan-Meyer curves of ATRS/S;Rrm2+/+ (n = 25) and ATRS/S;
Rrm2+/TG (n = 26) mice. The P-value was calculated with the Man-
tel-Cox log rank test.
Rescue of ATR-Seckel with RRM2
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mutants besides mec1Δ (Poli et al. 2012). To what extent
increased RNR activity can also alleviate the phenotypes
of additional genomic instability-driven diseases in mam-
mals demands further investigation. Interestingly, folates,
the nucleotide precursors, are routinely used in medicine
for the prevention or treatment of awide range of diseases,
including various age-related pathologies. Our work sug-
gests that strategies directed to increase RNR activity
might also have beneficial effects in mammalian disease.
Collectively, our data validate Rrm2TG mice as a valua-
blemammalianmodel of increasedRNRactivity anddem-
onstrate that ATR-dependent regulation of nucleotide
pools contributes to the phenotypes of Seckel mice.
Materials and methods
Mouse models
For the generation ofRrm2TGmice, a 26-kb region from themouse genome
encompassing the Rrm2 gene was cloned from a BAC (RP23–460K8) into a
minimal vector by recombineering (Gene Bridges) and was subsequently
used for the generation of transgenicmice bymicroinjection into fertilized
oocytes. ATR-Seckel (Murga et al. 2009) mice have been described.
Nucleoside supplementation
Where indicated, a nucleoside solution commercialized as a supplement
for improving the growth of embryonic stem cells was used at the suggest-
ed dose (EmbryoMax ES Cell Qualified Nucleosides, Millipore).
Cell vability assays
The assay for measuring cell viability by HTM using TO-PRO-3 and
Hoechst 33342 has been described before (Eguren et al. 2014).
Extended methods are in the Supplemental Material.
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